A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site

Japanese Journal of Clinical Oncology

Volumn 34, Issue 11, 2004, Pages 681-685

  Park, Yeon Hee ^a,b   Ryoo, Baek Yeol ^a   Choi, Seong Jun ^a   Yang, Sung Hyun ^a   Kim, Heung Tae ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b Korea Cancer Center Hospital   (South Korea)

Author keywords

Carcinoma of unknown primary site (CUP); Cisplatin; Paclitaxel

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HUMAN; IDIOPATHIC DISEASE; KOREA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PROGNOSIS; ADULT; AGED; ALOPECIA; CHEMICALLY INDUCED DISORDER; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FEMALE; LEUKOPENIA; MALE; MIDDLE AGED; MORTALITY; NEOPLASM; REVIEW;

ADENOCARCINOMA; ADULT; AGED; ALOPECIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; NEUTROPENIA; PACLITAXEL;

EID: 16644368148     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyh124     Document Type: Article

References (26)

1. Greco FA, Hainsworth JD. Cancer of unknown primary site. In: DeVita VT Jr, Hellman S, Rosenburg SA, editors. Cancer: Principles and Practice of Oncology, 6th edn. Philadelphia: Lippincott 2001;2537-60.
2. Baron PL, Moore MP, Kinne SW, et al. Occult breast cancer presenting with axillary metastases, updated management. Arch Surg 1990;125:210-4.
3. Ellerbroek N, Holmes F, Singletary E, et al. Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer 1990;66:1461-7.
4. Strand C, Grosh WW, Baxter JW. Peritoneal carcinomatosis of unknown primary site in women. Ann Intern Med 1989;111:213-7.
5. Hainsworth JD, Dial TW, Greco FA. Curative combination chemotherapy for patients with advanced poorly differentiated carcinoma of unknown primary site. Am J Clin Oncol 1988;11:138-45.
6. Wang RC, Goepfert H, Barber AE, Wolf P. Unknown primary squamous cell carcinoma metastatic to the neck. Arch Otolaryngol Head Neck Surg 1990;116:1388-93.
7. Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 1992;10:912-22.
8. Hainsworth JD, Erland JB, Kalmn CA, et al. Carcinoma of unknown primary site: treatment with one-hour paclitaxel, carboplatin and extended schedule etoposide. J Clin Oncol 1997;15:2385-93.
9. Greco FA, Burris HA, Erland JB, et al. Carcinoma of unknown primary site: long-term follow-up after treatment with paclitaxel, carboplatin, and etoposide. Cancer 2000;89:2655-60.
10. Greco FA, Erland JB, Morrissey LH, et al. Phase II trials with docetaxel plus cisplatin or carboplatin in carcinoma of unknown primary site. Ann Oncol 2000;11:211-5.
11. Greco FA, Gray J, Burris HA, et al. Taxane-based chemotherapy for patients with carcinoma of unknown primary site. Cancer J 2001;7:203-12.
12. Adamo V, Ferraro G, Pergolozzi, et al. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncol 2004;40:525-31.
13. Sakai H, Yoneda S, Tamura T, et al. A phase II study of paclitaxel plus cisplatin for advanced non-small-cell lung cancer in Japanese patients. Cancer Chemother Pharmacol 2001;48:499-503.
14. Park DC, Kim JH, Lew YO, et al. Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer. Gynecol Oncol 2004;92:59-63.
15. Dreicer R, Manola J, Roth BJ, et al. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group study. J Clin Oncol 2000;18:1058-61.
16. Dimopoulos MA, Papadimitriou CA, Georgoulias V, et al. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gynecol Oncol 2000;78:52-7.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000;92:205-16.
18. Greco FA, Burris HA, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 2002;20:1651-6.
19. Balana C, Manzano JL, Moreno I, et al. A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site. Ann Oncol 2003;14:1425-9.
20. Pouessel D, Culine S, Becht C, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer 2004;100:1257-61.
21. Dowell JE, Garrett AM, Shyr Y, et al. A randomized phase II trial in patients with carcinoma of an unknown primary site. Cancer 2001;91:592-7.
22. Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group study. J Clin Oncol 2000;18:3101-7.
23. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003;39:1990-2005.
24. Blaszyk H, Hartmann A, Bjornsson J. Cancer of unknown primary: clinicopathologic correlations. APMIS 2003;111:1089-94
25. Choi BK, Yuh YJ, Yang JH, et al. The efficacy of PEFL chemotherapy and identification of favourable subgroups in patients with carcinomas of unknown primary origin. J Kor Cancer Assoc 1999;31:144-52.
26. Greco FA, Erland JB, Morrissey LH, et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 2000;11:211-5.